17 completed, 6 terminated, 3 withdrawn, 2 unknown. 15 Phase 1, 14 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 11, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 14 | Completed 8, Terminated 3, Withdrawn 2, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Infinity Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel - Breast Cancer, Renal Cell Carcinoma | Phase 2 | Unknown | Infinity Pharmaceuticals, Inc. | 91 | 2019-12-17 | 2023-08-14 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) IPI-549 (eganelisib), Nivolumab, Placebos - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 49 | 2019-09-25 | 2022-11-25 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD) - TNBC - Triple-Negative Breast Cancer, Ovarian Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 35 | 2018-10-15 | 2024-05-24 |
| A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor Duvelisib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Withdrawn | AbbVie | 2016-07-01 | 2016-07-26 | |
| A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 IPI-549 (eganelisib), Nivolumab - Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E) | Phase 1 | Unknown | Infinity Pharmaceuticals, Inc. | 219 | 2015-12-01 | 2022-04-04 |
| Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma duvelisib - Lymphoma | Phase 1 | Completed | AbbVie | 7 | 2015-11-01 | 2017-02-06 |
| IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) IPI-145, Follow-up Visit/Call - Leukemia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2013-12-01 | 2014-01-06 | |
| Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies IPI-145, Rituximab, Bendamustine - Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | SCRI Development Innovations, LLC | 48 | 2013-05-01 | 2016-07-11 |
| IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 IPI-926 - Basal Cell Carcinoma, Chondrosarcoma | Not applicable | Completed | Infinity Pharmaceuticals, Inc. | 9 | 2012-03-01 | 2012-11-14 |
| A Phase 2 Study With IPI-926 in Patients With Myelofibrosis IPI-926 - Primary Myelofibrosis, Fibrosis, Bone Marrow | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 14 | 2011-10-01 | 2012-11-15 |
| FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma FOLFIRINOX, IPI-926 - Pancreatic Cancer, Adenocarcinoma | Phase 1 | Completed | Andrew Ko | 15 | 2011-08-23 | 2017-08-08 |
| Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer IPI-504, Everolimus - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 47 | 2011-07-01 | 2014-11-13 |
| A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer IPI 504 plus Docetaxel, Placebo plus Docetaxel - Non Small Cell Lung Cancer | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 226 | 2011-05-01 | 2014-05-19 |
| A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma IPI-926, Placebo Arm - Conventional Chondrosarcoma | Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 105 | 2011-02-01 | 2013-12-05 |
| IPI-504 in NSCLC Patients With ALK Translocations IPI-504 - Lung Cancer, Stage IIIb Lung Cancer | Phase 2 | Terminated | Massachusetts General Hospital | 3 | 2010-10-01 | 2017-12-04 |
| Dose Escalation of IPI-493 in Hematologic Malignancies IPI-493 - Hematologic Malignancies | Phase 1 | Terminated | Infinity Pharmaceuticals, Inc. | 4 | 2010-06-01 | 2015-04-15 |
| A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer IPI-926 plus gemcitabine, Placebo plus gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Infinity Pharmaceuticals, Inc. | 122 | 2010-04-01 | 2017-03-06 |
| Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma IPI-504 - Dedifferentiated Liposarcoma | Phase 2 | Withdrawn | Infinity Pharmaceuticals, Inc. | 2010-01-01 | 2015-04-14 | |
| Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer IPI-504, Trastuzumab - Breast Cancer, HER2 Positive Breast Cancer | Phase 2 | Terminated | Infinity Pharmaceuticals, Inc. | 29 | 2009-03-01 | 2012-12-11 |
| A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies IPI-926 - Neoplasms | Phase 1 | Completed | Infinity Pharmaceuticals, Inc. | 94 | 2008-09-01 | 2012-06-21 |
Showing 20 of 28. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (4) · Hematologic Neoplasms (3) · Lung Neoplasms (3) · Lymphoma (3) · Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Gastrointestinal Stromal Tumors (2) · Leukemia (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Melanoma (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Adenocarcinoma (1)
tanespimycin (14) · IPI-926 (6) · IPI-549 (4) · duvelisib (4) · Docetaxel (2) · Nivolumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Everolimus (1) · Fluorouracil (1) · Gemcitabine (1) · HSP90 Heat-Shock Proteins (1) · Irinotecan (1)
United States (25) · Canada (4) · Australia (2) · France (2) · Italy (2) · Poland (2) · Russia (2) · Spain (2) · Austria (1) · Czechia (1) · Germany (1) · Hungary (1) · Japan (1) · Netherlands (1) · Norway (1)
Robert Ross, MD (3) · Pedro Santabarbara, M.D. (2) · Pedro Santabarbara, MD (2) · Tess Schmalbach, MD (2) · Andrew Ko, M.D. (1) · David S. Siegel, MD; Ph.D (1) · Feng Chi, MD (1) · Feng Chi, PhD, RN (1) · George D Demetri, MD, PhD (1) · George Demetri, MD (1) · Gregory Riely, MD (1) · Halle Zhang, PhD, RN (1) · Ian Flinn, M.D. (1) · Ivan Borrello, MD (1) · John Hayslip, MD (1)
2015 (1)